SCHEMBL12434151

SCHEMBL12434151

CC(C)(C)OC(=O)NCc1ccccc1-c1ccccc1C(=O)NCc1cccnc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 4/20 0.62
HTT P42858 3/20 0.59
KMT2A Q03164 1/20 0.59
ALDH1A1 P00352 4/20 0.55
KCNK3 O14649 1/20 0.55
KCNH2 Q12809 1/20 0.55
CYP3A4 P08684 1/20 0.54
USP2 O75604 1/20 0.54
HPGD P15428 1/20 0.53
TSHR P16473 1/20 0.53
LMNA P02545 2/20 0.53
NAMPT P43490 1/20 0.53
MAPK1 P28482 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
EPHX1 P07099 1/20 0.50
RECQL P46063 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12434153 0.91 KCNK3 (0.67) KCNA5HTTKMT2AALDH1A1KCNK3
SCHEMBL12434473 0.88 KCNA5 (0.71) KCNA5KMT2AALDH1A1KCNK3HPGD
SCHEMBL479925 0.83 CYP3A4 (0.72) HTTKMT2AALDH1A1CYP3A4TSHR
SCHEMBL12434382 0.83 ALDH1A1 (0.63) KCNA5HTTKMT2AALDH1A1KCNK3
SCHEMBL12434147 0.81 KCNA5 (0.64) KCNA5HTTKMT2AALDH1A1KCNK3
SCHEMBL12434478 0.81 KCNA5 (0.73) KCNA5KCNK3KCNH2
SCHEMBL12434240 0.80 KCNA5 (0.63) KCNA5KCNK3
SCHEMBL13789496 0.80 KCNA5 (0.60) KCNA5KCNK3HPGDLMNA
SCHEMBL12434231 0.80 KCNA5 (0.60) KCNA5KMT2ACYP3A4HPGDLMNA
SCHEMBL12434086 0.79 KCNK3 (0.84) KCNA5HTTKMT2AALDH1A1KCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-7982045-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-19 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-07-30 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192096-A1 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them MLLT3, RYR2, CACNA1E KCNA5 90/4885HTT 3597/4885KMT2A 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.